108 artigos
The fourth-tier hallmarks — regenerative decline, altered tissue signaling, inflammaging and gut dysbiosis — are the ones that actually walk into clinic. How to measure them with a dynamometer, a hallway and a short lab panel, and which single prescription moves several at once.
The three aging processes that begin as protective responses and become drivers — what can actually be measured in clinic today, and where the human evidence for rapamycin, metformin, NAD precursors and senolytics genuinely stands.
Uma exploração mecanicista aprofundada de como a deficiência de B12 remodela o epigenoma do cérebro que envelhece, alimenta a neuroinflamação e exige estratégias de correção individualizadas que vão além dos protocolos de dosagem padrão.
A clinical read of the five upstream hallmarks — genomic instability, telomere attrition, epigenetic drift, loss of proteostasis and disabled autophagy — separating what is measurable in a patient from what is mechanism only, and what has human endpoint data from what does not.
How self-tolerance is enforced and how it fails, why an HLA risk genotype is not a prediction, and how to use — and not misuse — autoantibodies in the years before symptoms appear.
A clinical account of where cancer can actually be interrupted — germline syndromes that change management now, the metabolic and inflammatory contribution, and the hard line between screens with mortality data and screens with detection data only.
Domine a ciência molecular de ponta da fibrose mediada por TGF-β — desde a reprogramação epigenética e a mecanotransdução até as estratégias terapêuticas de próxima geração que visam nós específicos da via em tecidos que envelhecem.
A sequenced account of the advanced longevity workup — genome, blood, imaging, function, microbiome, proteomics, liquid biopsy — with a stated confidence on every element and a method for turning fifty abnormal values into one first action.
A clinical walkthrough of the Alzheimer's cascade, APOE ε4 counseling, the plasma biomarkers that made pre-symptomatic detection real, and the risk-reduction plan the evidence actually supports — plus the Parkinson's prodrome you can ask about in a routine history.
A clinical framework for atherosclerosis as lifetime particle exposure rather than a ten-year risk percentage — how to combine apoB, Lp(a), coronary imaging and inherited risk into a decision about when to start treating, and how to explain a 'normal' lipid panel that isn't reassuring.
Type 2 diabetes is the late visible stage of a storage problem that begins years earlier. How to detect metabolic dysfunction while fasting glucose and HbA1c are still normal, how to stage the liver without a biopsy, and how to sequence the response.
Explore a arquitetura molecular avançada da sinalização de estresse purinérgico — do reprogramação transcricional e do crosstalk metabólico às estratégias terapêuticas emergentes que visam CD38, P2X7 e o eixo ectonucleotidase no envelhecimento.
